Blog

To view blog posts prior to July 2010, click here.

The Memphis Business Group on Health (MBGH) is pleased to make this forum, including all web pages and web sites accessed from this page, available to Web Site users and others. However, the MBGH does not render legal or consultation services, and legal counsel must be consulted to determine any material’s applicability to any specific situation. MBGH cannot warrant or control the quality, accuracy, or validity of the information posted here. Comments posted on this blog are the sole responsibility of their writers. Use of such information is at the risk of the accessing user and the accessing user assumes all liabilities that may result from such use.


Category: Specialty Medications

New, Very Expensive Treatments for Cholesterol Approved

NOTE: MBGH's new, specialty pharmacy management program for members is exactly what employers need to make the tough decisions around how to manage the costs of the new, very expensive treatments for high cholesterol, while still getting this treatment to those that need it. Contact Cristie at ctravis@memphisbusinessgroup.org to learn more. Two drugs in a new class of cholesterol-lowering treatments have now been approved by the FDA --  Praluent, made by Sanofi Regeneron... Read More
Posted by Cristie Travis at Monday, August 31, 2015 | 0 comments

How Does Your Health Plan Treat the New Biosimilars?

2015 MBGH Specialty Pharmacy Management Workshop Topic (held April 1) From the National Business Coalition on Health: "Earlier this month, Novartis’ Zarxio was the first biosimilar product approved in the United States, ushering in a new era for the drug industry, consumers and third parties who manage medical and drug benefits. The introduction of cheaper alternatives to relatively complex biologic drugs has created confusion over the U.S. Food and Drug Administration’s approval process... Read More
Posted by Cristie Travis at Tuesday, April 14, 2015 | 0 comments

CVS Urges Cost Controls For New Cholesterol Medications

Citing the concern that eventually 15 million patients at an annual cost of $150 billion of a new class of cholesterol medications, CVS Health warned that the cost of these new medications could overwhelm the U.S. health care system "if rigid cost control mechanisms are not put in place". According to Reuters, CVS negotiates drug pricing for 65 million through contracts with employers and health plans. The concerns around cholesterol medications are closely following criticism regarding the... Read More
Posted by Cristie Travis at Wednesday, February 18, 2015 | 0 comments

Specialty Drugs to Account for 50% of Pharmacy Spend by 2018

Wonder why specialty drugs are likely to account for 50% of pharmacy spend by 2018? Here are three reasons: Supply and demand. Only 3.6% of the commercial population use specialty drugs so the market for these drugs is very small. On the other hand, the development costs are very high, resulting in high costs per patient. No generics . Specialty drugs are often too complex to be produced under generic requirements. LImitations on price increases once on the market. Manufacturers... Read More
Posted by Cristie Travis at Monday, October 27, 2014 | 0 comments

September 29 Webinar: Access to Specialty Medications & Value-based Insurance Design

Join the National Pharmaceutical Council for a webinar on September 29 from 12:00-1:00 CT.  NBCH's CEO, Brian Klepper, will present on the webinar along with a panel of other leading health and benefits experts. Read the webinar announcement from NPC below and register online today .  Specialty medications have been making health care headlines in recent months because of their effectiveness and higher costs. How can we ensure that patients will have access to the treatments that... Read More
Posted by Cristie Travis at Wednesday, September 17, 2014 | 0 comments


Say Hello

Please feel free to drop us a line via the button below. We try to respond to every email we receive.

Stay Connected

Join the MBGH community and keep up to date with issues concerning Memphis healthcare.

Facebook Twitter LinkedIn Feed